October 19, 2010Pharmacogenetics and Genomics
Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics
Why the study?
Do fibrates reduce fasting plasma triglycerides differently across hypertriglyceridemia phenotypes with different genetic and clinical characteristics?
Population
146 fasting adults with hypertriglyceridemia, including 15 with lactescent plasma and severe…
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Supports genotype-informed fibrate selection in hypertriglyceridemia; leaves open confirmation by genotype-stratified RCTs.
Structured PICO
Do fibrates reduce fasting plasma triglycerides differently across hypertriglyceridemia phenotypes with different genetic and clinical characteristics?
P
Population
146 fasting adults with hypertriglyceridemia, including 15 with lactescent plasma and severe hypertriglyceridemia (triglyceride ≥ 10 mmol/l) and 131 with clear plasma and moderate hypertriglyceridemia (2 ≤ triglycerides <10 mmol/l)
I
Intervention
Fibrates
O
Outcome
Fasting plasma triglycerides and other lipids levelssurrogate
Genetic factors underlying hypertriglyceridemia subtypes significantly modulate the lipid-lowering response to fibrates.
Cite This Study
Brisson et al. (2010) studied this question.